Literature DB >> 3474084

Methotrexate in neutrophils in children with acute lymphoblastic leukemia.

H Schrøder.   

Abstract

Methotrexate (MTX) and 6-mercaptopurine (6-MP) are used for maintenance therapy of acute lymphoblastic leukemia (ALL) of childhood, and both are myelotoxic. Clinically the individual tolerance to the two drugs is variable. In order to study to what extent the MTX accumulation in circulating neutrophils is related to the absolute neutrophil count (ANC), neutrophils were isolated on a discontinuous two-step Percoll gradient in 16 children with ALL in maintenance therapy. The MTX concentration in the neutrophils was determined with a sensitive radioligand binding assay. In all children except one who admitted noncompliance, MTX was found in the neutrophils in concentrations (56-460 pmol/10(9) cells) positively correlated with the weekly dose of MTX (r = 0.51, p less than 0.01). The interindividual variation was large. Children with relatively low neutrophil MTX exhibited the widest intraindividual variation of neutrophil MTX upon reexamination during continued MTX administration with the same dosage schedule. Increases in the weekly dose of MTX resulted in proportional increases in the neutrophil MTX. In half the cases the ANC was less than 1.5 X 10(9)/l. The ANC was not related to the weekly MTX dose or the daily 6-MP dose. In children with ANC greater than 1.5 X 10(9)/l there was a significant inverse correlation between the ANC and the neutrophil MTX (r = -0.71, P less than 0.01), which was not found in the group of children with ANC less than 1.5 X 10(9)/l. These findings may be explained by differences in the kinetics of the granulopoiesis between children with high and children with low neutrophil counts.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3474084     DOI: 10.1007/BF00261485

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  MITOTIC INDICES OF HUMAN BONE MARROW CELLS. 3. DURATION OF SOME PHASES OF ERYTHROCYTIC AND GRANULOCYTIC PROLIFERATION COMPUTED FROM MITOTIC INDICES.

Authors:  S A KILLMANN; E P CRONKITE; T M FLIEDNER; V P BOND
Journal:  Blood       Date:  1964-09       Impact factor: 22.113

2.  A rapid, radiochemical-ligand binding assay for methotrexate.

Authors:  B A Kamen; P L Takach; R Vatev; J D Caston
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

Review 3.  The cellular pharmacology of methotrexate.

Authors:  I D Goldman; L H Matherly
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

Review 4.  Kinetics of granulocytopoiesis.

Authors:  E P Cronkite
Journal:  Clin Haematol       Date:  1979-06

5.  Drug dosage and remission duration in childhood lymphocytic leukemia.

Authors:  D Pinkel; K Hernandez; L Borella; C Holton; R Aur; G Samoy; C Pratt
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

6.  Modes of uptake of methotrexate by normal and leukemic human leukocytes in vitro and their relation to drug response.

Authors:  D Kessel; T C Hall; D Roberts
Journal:  Cancer Res       Date:  1968-03       Impact factor: 12.701

7.  A rapid one-step method for the isolation of human granulocytes from whole blood.

Authors:  L V Jepsen; T Skottun
Journal:  Scand J Clin Lab Invest       Date:  1982-05       Impact factor: 1.713

8.  Marrow cell kinetics in patients treated with methotrexate and citrovorum factor.

Authors:  W R Vogler; Z H Israili; A G Soliman; S Moffitt; B Barlogie
Journal:  Cancer       Date:  1981-01-15       Impact factor: 6.860

9.  Synthesis of methotrexate polyglutamates by bone marrow cells from patients with leukemia and lymphoma.

Authors:  A Witte; V M Whitehead; D S Rosenblatt; M J Vuchich
Journal:  Dev Pharmacol Ther       Date:  1980

10.  Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment.

Authors:  H Schrøder; N Clausen; E Ostergaard; T Pressler
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more
  1 in total

1.  In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes.

Authors:  H Schrøder; K Fogh; T Herlin
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.